Tag: 1

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.¹ The results showed that TALVEY^® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).¹ Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.¹  

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

佛罗里达州迈阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 随着 SpaceX (纳斯达克代码：SPCX) 预计今日在纳斯达克开始交易，Defiance ETFs 证实，旗下 Defiance Daily 2X Space ETF (芝加哥期权交易所代码：SPCL) 将寻求在其投资组合中对 SpaceX A 类普通股提供 2 倍每日杠杆风险敞口。这使得该基金成为 SpaceX 上市首日首个也是唯一一个提供 2 倍杠杆风险敞口的美国 ETF。该基金按照 135 美元的 IPO 发行价确定了对 SpaceX 的风险敞口。

佛羅里達州邁阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 預期 SpaceX (NASDAQ: SPCX) 今日將於 Nasdaq 開始買賣，Defiance ETFs 確認，Defiance Daily 2X Space ETF (Cboe: SPCL) 會在其投資組合中尋求對 SpaceX A 類普通股提供 2 倍每日槓桿曝險，令其成為首隻及唯一在上市首日提供 2 倍 SpaceX 曝險的美國交易所買賣基金 (ETF)。該基金以 135 美元的首次公開招股 (IPO) 價建立其 SpaceX 曝險。

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.